Home / Market Reports / Pharma & Healthcare
/ Global Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth (Status and Outlook) 2024-2030
Global Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth (Status and Outlook) 2024-2030
Product Code:1228011
Published Date: Sep 26,2024
Pages: 87
Region: Global
Category: Pharma & Healthcare
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
Antibody Oligonucleotide Conjugates(AOC) Drug are a new class of synthetic bioconjugates consisting of monoclonal antibodies and oligonucleotides (ONs), which have attracted considerable attention in the application of modern biotechnology. In recent years, biopharmaceutical companies have focused a lot of attention and resources on the development of advanced drugs based on AOC technology. Companies such as Avidity, Dyne, Tallac, Denali, and Gennao Bio are developing treatments for various muscle diseases, such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy, as well as cancer and central nervous system diseases.
The global Antibody Oligonucleotide Conjugates(AOC) Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Antibody Oligonucleotide Conjugates(AOC) Drug Industry Forecast” looks at past sales and reviews total world Antibody Oligonucleotide Conjugates(AOC) Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Antibody Oligonucleotide Conjugates(AOC) Drug sales for 2023 through 2029. With Antibody Oligonucleotide Conjugates(AOC) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody Oligonucleotide Conjugates(AOC) Drug industry.
This Insight Report provides a comprehensive analysis of the global Antibody Oligonucleotide Conjugates(AOC) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody Oligonucleotide Conjugates(AOC) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody Oligonucleotide Conjugates(AOC) Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody Oligonucleotide Conjugates(AOC) Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody Oligonucleotide Conjugates(AOC) Drug.
United States market for Antibody Oligonucleotide Conjugates(AOC) Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Antibody Oligonucleotide Conjugates(AOC) Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Antibody Oligonucleotide Conjugates(AOC) Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Antibody Oligonucleotide Conjugates(AOC) Drug players cover Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Denali Therapeutics, Gennao Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody Oligonucleotide Conjugates(AOC) Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antisense Oligonucleotide(ASO) Based
Small Interfering RNA(siRNA) Based
Aptamer Based
Segmentation by Application:
DMI
DMD
FSHD
Cancer
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Antisense Oligonucleotide(ASO) Based
Small Interfering RNA(siRNA) Based
Aptamer Based
Segmentation by Application:
DMI
DMD
FSHD
Cancer
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio
Ractigen Therapeutics